Let me verify the specific case and the Zydus International entity.
Let me verify the parent group's current size and the nature of the Irish entity's role.
Company overview. Zydus International Private Limited (commonly "Zydus International") is an Irish private limited company, registered number 285240, incorporated 30 April 1998, with its registered office at FDW House, Blackthorn Business Park, Coes Road, Dundalk, Co. Louth, Ireland. It is a 100%-owned subsidiary of Zydus Lifesciences Limited (formerly Cadila Healthcare Limited), headquartered in Ahmedabad, India, and listed on the NSE/BSE (ZYDUSLIFE / 532321). The parent reported FY2025 revenue of roughly ₹23,240 crore (~US$2.4–2.7bn) with about 23,000–28,000 employees, depending on source.
Operations. Zydus International is a group holding/finance vehicle, not an operating manufacturer. Irish filings classify it as a small company whose principal activity is "other business activities N.E.C.," with turnover of about €4.8m (FY2022) and €4.5m (FY2019); it was the acquiring entity in the group's 2017 Etna Biotech S.R.L. share purchase. The group's operating businesses are generic and branded pharmaceuticals, active pharmaceutical ingredients, biosimilars, vaccines and consumer wellness, with US generics sold through sister company Zydus Pharmaceuticals (USA) Inc. (Pennington, New Jersey), which had filed over 290 ANDAs as of 2022.
Patent-litigation posture. The case data show one tracked matter, as defendant and none as plaintiff — consistent with an operating pharmaceutical group defending Hatch-Waxman patent suits brought by innovator companies, not a patent-assertion vehicle. The single tracked venue is the U.S. District Court for the District of New Jersey, where Zydus Pharmaceuticals (USA) is incorporated; there is no Eastern District of Texas exposure in the data.
Notable case. Celgene Corporation v. Zydus Pharmaceuticals (USA) Inc. et al., No. 2:17-cv-02528 (D.N.J.), filed 12 April 2017, arose from Zydus's Paragraph IV ANDA for generic lenalidomide (REVLIMID®). Celgene and Zydus announced a settlement on 24 March 2021, with consent judgments enjoining Zydus from marketing generic lenalidomide before patent expiry except as permitted by the agreement. I could not verify Zydus International's specific role as a named defendant in that docket from the sources reviewed.